Multi-institutional assessment of adverse health outcomes among north American testicular cancer survivors after modern cisplatin-based chemotherapy

Journal of Clinical Oncology

Volumn 35, Issue 11, 2017, Pages 1211-1222

  Fung, Chunkit ^a   Sesso, Howard D ^c   Williams, Annalynn M ^a   Kerns, Sarah L ^a   Monahan, Patrick ^e   Zaid, Mohammad Abu ^e   Feldman, Darren R ^b   Hamilton, Robert J ^f   Vaughn, David J ^h   Beard, Clair J ^d   Kollmannsberger, Christian K ^g   Cook, Ryan ^e   Althouse, Sandra ^e   Ardeshir Rouhani Fard, Shirin ^e   Lipshultz, Steve E ^i,j,k   Einhorn, Lawrence H ^e   Fossa, Sophie D ^l,o   Travis, Lois B ^e   Curreri, Stephanie ^d   Brames, Mary Jacqueline ^e   Norton, Kelli ^e   Jacobsen, Erin ^b   Silber, Deborah ^b   Anson Cartwright, Lynn ^f   Cox, Nancy J ^m   Dolan, M Eileen ^m   Jacobs, Linda ^h   Panzer, Sarah Lena ^h   Pucci, Donna ^h   Baker, Debbie ^a   Casaceli, Cindy ^a   Johnson, Eileen ^a   Sahasrabudhe, Deepak ^a   Frisina, Robert D ⁿ   Bosl, George ^b   Gospodarowicz, Mary ^f   Robison, Leslie L ^p   more..

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^k KARMANOS CANCER INSTITUTE   (United States)

^l OSLO UNIVERSITY HOSPITAL   (Norway)

^m UNIVERSITY OF CHICAGO   (United States)

ⁿ UNIVERSITY OF SOUTH FLORIDA   (United States)

^o OSLO UNIVERSITY HOSPITAL   (Norway)

^p ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGE; ANDROGEN THERAPY; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; FOLLOW UP; GERM CELL TUMOR; HEALTH BEHAVIOR; HEARING IMPAIRMENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGONADISM; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OBESITY; PATIENT-REPORTED OUTCOME; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PHYSICAL ACTIVITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUESTIONNAIRE; RAYNAUD PHENOMENON; RISK FACTOR; SMOKING; TESTIS CANCER; THROMBOEMBOLISM; TINNITUS; WAIST CIRCUMFERENCE; AGED; CANADA; CASE CONTROL STUDY; CHEMICALLY INDUCED; CLINICAL TRIAL; EXERCISE; HEALTH STATUS; HEARING LOSS; LONG TERM ADVERSE EFFECTS; MIDDLE AGED; MULTICENTER STUDY; PERIPHERAL NERVOUS SYSTEM DISEASES; PREVALENCE; PROTECTION; RAYNAUD DISEASE; STATISTICS AND NUMERICAL DATA; SURVIVOR; TESTICULAR NEOPLASMS; UNITED STATES; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CANADA; CASE-CONTROL STUDIES; CISPLATIN; ETOPOSIDE; EXERCISE; HEALTH STATUS; HEARING LOSS; HUMANS; LONG TERM ADVERSE EFFECTS; MALE; MIDDLE AGED; OBESITY; PERIPHERAL NERVOUS SYSTEM DISEASES; PREVALENCE; PROTECTIVE FACTORS; RAYNAUD DISEASE; RISK FACTORS; SMOKING; SURVEYS AND QUESTIONNAIRES; SURVIVORS; TESTICULAR NEOPLASMS; TINNITUS; UNITED STATES; YOUNG ADULT;

EID: 85017304402     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.3108     Document Type: Article

References (59)

1. Verdecchia A, Francisci S, Brenner H, et al: Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796, 2007
2. Einhorn LH, Donohue J: Cisdiamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293-298, 1977
3. Albers P, Albrecht W, Algaba F, et al: Guidelines on testicular cancer: 2015 update. Eur Urol 68: 1054-1068, 2015
4. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Testicular Cancer (Version 2.2016), https://www.nccn. org/professionals/physician-gls/pdf/testicular.pdf
5. Oldenburg J, Foss°a SD, Nuver J, et al: Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi125-vi132, 2013 (suppl 6)
6. International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594-603, 1997
7. Hanna N, Einhorn LH: Testicular cancer: A reflection on 50 years of discovery. J Clin Oncol 32: 3085-3092, 2014
8. Hanna NH, Einhorn LH: Testicular cancer- discoveries and updates. N Engl J Med 371: 2005-2016, 2014
9. Oldenburg J, Gietema JA: The sound of silence: A proxy for platinum toxicity. J Clin Oncol 34: 2687-2689, 2016
10. Haugnes HS, Wethal T, Aass N, et al: Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 28:4649-4657, 2010
11. Huddart RA, Norman A, Shahidi M, et al: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21: 1513-1523, 2003
12. Bokemeyer C, Berger CC, Kuczyk MA, et al: Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14:2923-2932, 1996
13. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al: Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25: 4370-4378, 2007
14. Dahl CF, Haugnes HS, Bremnes R, et al: A controlled study of risk factors for disease and current problems in long-term testicular cancer survivors. J Cancer Surviv 4:256-265, 2010
15. Miller KD, Siegel RL, Lin CC, et al: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271-289, 2016
16. Elena JW, Travis LB, Simonds NI, et al: Leveraging epidemiology and clinical studies of cancer outcomes: Recommendations and opportunities for translational research. J Natl Cancer Inst 105:85-94, 2013
17. Travis LB, Beard C, Allan JM, et al: Testicular cancer survivorship: Research strategies and recommendations. J Natl Cancer Inst 102:1114-1130, 2010
18. Frisina RD, Wheeler HE, Fossa SD, et al: Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol 34:2712-2720, 2016
19. Geenen MM, Cardous-Ubbink MC, Kremer LC, et al: Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA 297:2705-2715, 2007
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
21. Oldenburg J, Foss°a SD, Dahl AA: Scale for chemotherapy-induced long-term neurotoxicity (SCIN): Psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res 15:791-800, 2006
22. Ventry IM, Weinstein BE: The hearing handicap inventory for the elderly: A new tool. Ear Hear 3: 128-134, 1982
23. Postma TJ, AaronsonNK, Heimans JJ, et al: The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer 41:1135-9, 2005
24. Taylor HL, Jacobs DR Jr, Schucker B, et al: A questionnaire for the assessment of leisure time physical activities. J Chronic Dis 31:741-755, 1978
25. Chasan-Taber S, Rimm EB, Stampfer MJ, et al: Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology 7:81-86, 1996
26. Travis LB, Curtis RE, Stovall M, et al: Risk of leukemia following treatment for non- Hodgkin's lymphoma. J Natl Cancer Inst 86: 1450-1457, 1994
27. Travis LB, Curtis RE, Glimelius B, et al: Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 87:524-530, 1995
28. Travis LB, Holowaty EJ, Bergfeldt K, et al: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 340:351-357, 1999
29. Travis LB, Andersson M, Gospodarowicz M, et al: Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92:1165-1171, 2000
30. Travis LB, Gospodarowicz M, Curtis RE, et al: Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 94: 182-192, 2002
31. Travis LB, Hill DA, Dores GM, et al: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290:465-475, 2003
32. eClinicalWorks: eClinicalWorks: Improving Healthcare Together. https://www.eclinicalworks.com/
33. Nottage KA, Ness KK, Li C, et al: Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia - From the St. Jude Lifetime Cohort. Br J Haematol 165: 364-374, 2014
34. Haugnes HS, Bosl GJ, Boer H, et al: Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 30: 3752-3763, 2012
35. Nigam M, Aschebrook-Kilfoy B, Shikanov S, et al: Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol, 33:623-631, 2015
36. Ainsworth BE, Haskell WL, Herrmann SD, et al: 2011 Compendium of Physical Activities: A second update of codes and MET values. Med Sci Sports Exerc 43:1575-1581, 2011
37. Bokemeyer C, Berger CC, Hartmann JT, et al: Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77: 1355-1362, 1998
38. Brydøy M, Oldenburg J, Klepp O, et al: Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 101:1682-1695, 2009
39. Glendenning JL, Barbachano Y, Norman AR, et al: Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 116:2322-2331, 2010
40. Kim C, McGlynn KA, McCorkle R, et al: Quality of life among testicular cancer survivors: A casecontrol study in the United States. Qual Life Res 20:1629-1637, 2011
41. Oh JH, Baum DD, Pham S, et al: Long-term complications of platinum-based chemotherapy in testicular cancer survivors. Med Oncol 24:175-181, 2007
42. Reilley MJ, Jacobs LA, Vaughn DJ, et al: Health behaviors among testicular cancer survivors. J Community Support Oncol 12:121-128, 2014
43. Shinn EH, Basen-Engquist K, Thornton B, et al: Health behaviors and depressive symptoms in testicular cancer survivors. Urology 69:748-753, 2007
44. Gamazon ER, Wheeler HE, Frisina RD, et al: Variation in protein-coding sequence and the genetic basis of cisplatin-induced toxicities among testicular cancer survivors (TCS) in the Platinum Study. J Clin Oncol 34, 2016 (suppl; abstr 1537)
45. Travis LB, Fossa SD, Sesso HD, et al: Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst 106:1-11, 2014
46. Phillips SM, Padgett LS, Leisenring WM, et al: Survivors of childhood cancer in the United States: Prevalence and burden of morbidity. Cancer Epidemiol Biomarkers Prev 24:653-663, 2015
47. Aschim EL, Oldenburg J, Kristiansen W, et al: Genetic variations associated with the effect of testicular cancer treatment on gonadal hormones. Hum Reprod 29:2844-2851, 2014
48. Mykletun A, Dahl AA, Haaland CF, et al: Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol 23:3061-3068, 2005
49. Dahl AA, Haaland CF, Mykletun A, et al: Study of anxiety disorder and depression in long-term survivors of testicular cancer. J Clin Oncol 23:2389-2395, 2005
50. Fleer J, Hoekstra HJ, Sleijfer DT, et al: Quality of life of testicular cancer survivors and the relationship with sociodemographics, cancer-related variables, and life events. Support Care Cancer 14: 251-259, 2006
51. Finegold JA, Asaria P, Francis DP: Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol 168:934-945, 2013
52. Hudson MM, Mertens AC, Yasui Y, et al: Health status of adult long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. JAMA 290:1583-1592, 2003
53. Byers TE, Wolf HJ, Bauer KR, et al: The impact of socioeconomic status on survival after cancer in the United States: Findings from the National Program of Cancer Registries Patterns of Care Study. Cancer 113:582-591, 2008
54. Aizer AA, Chen MH, McCarthy EP, et al: Marital status and survival in patients with cancer. J Clin Oncol 31:3869-3876, 2013
55. Foss°a SD, Cvancarova M, Chen L, et al: Adverse prognostic factors for testicular cancer-specific survival: A population-based study of 27, 948 patients. J Clin Oncol 29:963-970, 2011
56. Osanto S, Bukman A, Van Hoek F, et al: Longterm effects of chemotherapy in patients with testicular cancer. J Clin Oncol 10:574-579, 1992
57. Oeffinger KC, Mertens AC, Sklar CA, et al: Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572-1582, 2006
58. Robison LL, Armstrong GT, Boice JD, et al: The Childhood Cancer Survivor Study: A National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 27:2308-2318, 2009
59. Charif OE, Wheeler HE, Mushiroda T, et al: Genome-wide association study of cisplatin-induced peripheral neuropathy (CIPN) in testicular cancer survivors. J Clin Oncol 34, 2016 (suppl; abstr 4543)